Shares of Taro Pharmaceutical Industries Ltd. (TARO) Sees Large Inflow of Net Money Flow

Taro Pharmaceutical Industries Ltd. (TARO) : Taro Pharmaceutical Industries Ltd. (TARO) had a healthy money flow of $0.39 million into the stock during the Fridays trading session. The value of bullish trades on upticks was $3.06 million, whereas, investors only sold shares worth $2.67 million on downticks. The stock closed the day with an up-down ratio of 1.15.The money flow in the block trades to the tune of $0 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $0 million worth of transactions were on upticks. Taro Pharmaceutical Industries Ltd. (TARO) stock slid $0.05 intraday and traded at 126.64, a change of -0.04% over previous days close. However, for the week, the company shares are -1.29% compared to previous weeks close.


The company Insiders own 13.8% of Taro Pharmaceutical Industries Ltd. shares according to the proxy statements. Institutional Investors own 16.24% of Taro Pharmaceutical Industries Ltd. shares.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO): stock was range-bound between the intraday low of $125.72 and the intraday high of $127.72 after having opened at $127.52 on Fridays session. The stock finally closed in the red at $127.52, a loss of -0.25%. The stock remained in the red for the whole trading day. The total traded volume was 151,218 shares. The stock failed to cross $127.72 in Fridays trading. The stocks closing price on Thursday was $126.69.

Taro Pharmaceutical Industries Ltd. (TARO) : During the past 4 weeks, traders have been relatively bearish on Taro Pharmaceutical Industries Ltd. (TARO), hence the stock is down -12.74% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2% relative to the S&P 500. The 4-week change in the price of the stock is -12.85% and the stock has fallen -1.5% in the past 1 week.

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company develops, manufactures and markets prescription (Rx) and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. Taro also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Companys primary areas of focus include semi-solids formulations, such as creams and ointments, and other dosage forms, such as liquids, capsules and tablets, primarily in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. Taros owned product brands include Rokacet, Topicort, Etopan, Lustra and Ovide. Its other generic products include acetazolamide, amiodarone hydrochloride, ammonium lactate, calcipotriene, carbamazepine, cetirizine hydrochloride, ciclopirox olamine, clindamycin, clobetasol propionate and clomipramine hydrochloride.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.